Ultragenyx is trading 4.64% up now at $26.50 as investors continue responding to the FDA’s accelerated approval of GENGLYCOS, announced August 19, 2026.

  • The approval is Ultragenyx’s first gene-therapy authorization and fifth FDA approval overall.
  • On August 20–21, H.C. Wainwright maintained a $50 target, while Canaccord raised its target to $83.
  • Biotech’s 2.02% gain is providing additional momentum.